Like nivolumab [20] and pembrolizumab [18], cetrelimab achieved tumor growth inhibition of MC38 tumors implanted on human PD-1 knock-in mice (companion paper by DeAngelis et al. in this issue of Cancer Chemotherapy and Pharmacology). The gene discussed is PDCD1; the disease is cancer.